Correlation between serum osteoprotegerin and biomarkers of bone metabolism during anti-thyroid treatment in patients with Graves' disease

Hormone Research

Volumn 66, Issue 5, 2006, Pages 236-239

  Mochizuki, Yasuhiro ^a   Banba, Nobuyuki ^a   Hattori, Yoshiyuki ^a   Monden, Tsuyoshi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Graves' disease; Osteoprotegerin; PTH; Thyroid hormone

Indexed keywords

ANTITHYROID AGENT; BIOCHEMICAL MARKER; CALCIUM; LIOTHYRONINE; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; PROPYLTHIOURACIL; PROTIRELIN; THIAMAZOLE; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADULT; ARTICLE; BONE ATROPHY; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GRAVES DISEASE; HUMAN; MALE; OSTEOCLAST; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REGRESSION ANALYSIS; THYROTROPIN BLOOD LEVEL;

ADULT; ANTITHYROID AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; FEMALE; GRAVES DISEASE; HUMANS; JAPAN; MALE; MIDDLE AGED; OSTEOPROTEGERIN;

EID: 33750188999     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095068     Document Type: Article

References (19)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliot R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Amgen EST Program, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
2. Khosla S: The OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055.
3. Langdahl BL, Loft AGR, Eriksen EF, Mosekilde L, Charles P: Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 1996;6:161-168.
4. Lanfdahl BL, Loft AGR, Eriksen EF, Mosekilde L, Charles P: Bone mass, bone turnover, calcium homeostasis, and body composition in surgically and radioiodine-treated former hyperthyroid patients. Thyroid 1996;6:169-175.
5. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y: Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000;85:4157-4161.
6. Siddiqi A, Burrin JM, Noonan K, James I, Wood DF, Price CP, Monson JP: A longitudinal study of markers of bone turnover in Graves' disease and their value in predicting bone mineral density. J Clin Endocrinol Metab 1997;82:753-759.
7. Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C: High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 2004;35:785-791.
8. Gao P, Scheibel S, D'amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL: Development of novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-614.
9. Varga F, Spitzer S, Klaushofer K: Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25 D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. Calcif Tissue Int 2004;74:382-387.
10. Abe E, Marinas RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M: TSH is a negative regulator of skeletal remodeling. Cell 2003;115:151-162.
11. Kisakol G, Kaya A, Gonen S, Tunc R: Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003;50:657-661.
12. Pantazi H, Papapetrou PD: Change in parameters of bone and mineral metabolism during therapy for hyperthyroidim. J Clin Endocrinol Metab 2000;85:1099-1106.
13. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD: Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001;86:3162-3165.
14. Lee S-K, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-3561.
15. Gonnelli S, Montagnani A, Caffarelli C, Cadirni A, Campagna MS, Franci MB, Lucani B, Gaggiotti E, Nuti R: Osteoprotegerin (OPG) and receptor activator of NF-κB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest 2005;28:534-539.
16. Nagasaki T, Inaba M, Jono S, Hiura Y, Tahara H, Shirakawa K, Onoda N, Ishikawa T, Ishimura E, Nishizawa Y: Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol 2005;152:347-353.
17. Guang-da X, Hui-ling S, Zhi-song C, Lin-shuang Z: Change in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J Clin Endocrinol Metab 2005;90:5765-5768.
18. Cappola AR, Ladenson PW: Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003;88:2438-2444.
19. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC, Schaefer JR: Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 2004;89:3764-3768.